Table 3. The frequency and overlapping duration of co-medicated patients according to generic name of statin in 2009.

Pattern	Total (n = 60,254)			Same prescription (n = 2,908)			Same medical institution (n = 8,000)			Different medical institutions (n = 51,369)
	Number	Overlapping days		Number (%)	Overlapping days		Number (%)	Overlapping days		Number (%)	Overlapping days
		Mean (±SE)	Median (Q1-Q3)		Mean (±SE)	Median (Q1-Q3)		Mean (±SE)	Median (Q1-Q3)		Mean (±SE)	Median (Q1-Q3)
Simvastatin	32,085	11.0 (±0.6)	7.1 (3.7–11.5)	1,754 (5.5)	9.1 (±1.2)	7.4 (5.4–7.9)	5,569 (17.4)	6.3 (±0.6)	5.3 (2.5–7.8)	25,938 (80.8)	11.8 (±0.7)	7.1 (3.8–13.1)
Atorvastatin	27,354	16.9 (±1.4)	7.9 (5.1–17.6)	1,138 (4.2)	12.1 (±2.0)	8.2 (4.0–14.9)	2,438 (8.9)	11.7 (±1.9)	7.3 (2.6–17.4)	24,600 (89.9)	17.2 (±1.6)	7.9 (5.2–17.4)
Lovastatin	1,300	11.1 (±2.8)	7.3 (5.6–9.3)	15 (1.2)	8.0 (±0)	8.0 (8.0–8.0)	23 (1.8)	6.0 (±2.5)	4.5 (1.0–8.2)	1,269 (97.6)	11.2 (±2.9)	7.2 (5.6–9.3)
Total	60,254	13.8 (±0.7)	7.4 (3.9–15.1)	2,908 (4.8)	10.1 (±1.0)	7.5 (5.4–12.1)	8,000 (13.3)	8.0 (±0.8)	4.7 (2.3–7.9)	51,369 (85.3)	14.5 (±0.8)	7.5 (4.2–15.3)

SE = Standard error, Q1 = quartile 1, Q3 = quartile 3.

Patients included in each type of co-medication pattern were not mutually exclusive.